PUBLISHER: DelveInsight | PRODUCT CODE: 1125976
PUBLISHER: DelveInsight | PRODUCT CODE: 1125976
"EMPAVELI/ASPAVELI Emerging Drug Insight and Market Forecast - 2032" report provides comprehensive insights about EMPAVELI/ASPAVELI for Cold Agglutinin Disease in the 7MM. A detailed picture of the EMPAVELI/ASPAVELI for Cold Agglutinin Disease in the 7MM, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2019-2032 is provided in this report along with a detailed description of the EMPAVELI/ASPAVELI for Cold Agglutinin Disease. The report provides insight about mechanism of action, dosage and administration, as well as research and development activity including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the EMPAVELI/ASPAVELI market forecast, analysis for Cold Agglutinin Disease in the 7MM, descriptive analysis such as SWOT, analyst views, comprehensive overview of market competitors, and brief about emerging therapies in Cold Agglutinin Disease.
EMPAVELI/ASPAVELI (Pegcetacoplan) is a PEGlyated pentadecapeptide which is being developed by the Apellis Pharmaceuticals in collaboration with Sobi Pharmaceuticals for the treatment of complement-mediated diseases. It binds to complement componenet 3 (C3) and also to its activation fragment C3b, controlling the cleavage of C3 and results in the generation of the downstream effectors of complement activation and thus both C3b-mediated extravascular hemolysis and terminal complement-mediated intravascular hemolysis. In May 2021, Pegcetacoplan became the first C3-targeted therapy to be approved for Paroxysmal nocturnal haemoglobinuria (PNH) to be approved in the US. Currently pegcetacoplan is also being investigated as a therapeutic option in other complement -mediated diseases including age-related macular degeneration, C3 glomeruloneuropathy and autoimmune hemolytic anemia including the Cold Agglutinin Disease (CAD).
The company has recently started a Phase III (NCT05096403) clinical study to test the drug for the treatment of CAD. The company is also conducting another Phase II (NCT03226678) for the treatment of patients with CAD. The anti-C3 cyclic peptide Pegcetacoplan appears to be a promisisng drug in the treatment of CAD, and may also have a therapeutic potential in the treatment of warm autoimmune hemolytic anemia.
The report provides insights into:
The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.
EMPAVELI/ASPAVELI Analytical Perspective by DelveInsight
This report provides a detailed market assessment of EMPAVELI/ASPAVELI in Cold Agglutinin Disease in the 7MM, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. This segment of the report provides forecasted sales data from 2025 to 2032.
The report provides the clinical trials information of EMPAVELI/ASPAVELI for Cold Agglutinin Disease covering trial interventions, trial conditions, trial status, start and completion dates.
Key Questions